FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

Stock Information for AIM ImmunoTech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AIM ImmunoTech Inc.

Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
FibroGen to Report Third Quarter 2025 Financial Results
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.